Table of Contents Author Guidelines Submit a Manuscript
Journal of Transplantation
Volume 2011 (2011), Article ID 374213, 7 pages
http://dx.doi.org/10.1155/2011/374213
Review Article

The Factors That May Predict Response to Rituximab Therapy in Recurrent Focal Segmental Glomerulosclerosis: A Systematic Review

Division of Pediatric Nephrology, University of Florida College of Medicine, 1600 SW Archer Road, Room HD-214, Gainesville, FL 32610-0296, USA

Received 20 July 2011; Accepted 11 October 2011

Academic Editor: Diego Cantarovich

Copyright © 2011 Carlos E. Araya and Vikas R. Dharnidharka. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. Kitiyakara, P. Eggers, and J. B. Kopp, “Twenty-one-year trend in ESRD due to focal segmental glomerulosclerosis in the United States,” American Journal of Kidney Diseases, vol. 44, no. 5, pp. 815–825, 2004. View at Publisher · View at Google Scholar · View at Scopus
  2. R. N. Fine, “Recurrence of nephrotic syndrome/focal segmental glomerulosclerosis following renal transplantation in children,” Pediatric Nephrology, vol. 22, no. 4, pp. 496–502, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  3. R. Bertelli, F. Ginevri, G. Caridi et al., “Recurrence of focal segmental glomerulosclerosis after renal transplantation in patients with mutations of podocin,” American Journal of Kidney Diseases, vol. 41, no. 6, pp. 1314–1321, 2003. View at Publisher · View at Google Scholar · View at Scopus
  4. A. Koyama, M. Fujisaki, M. Kobayashi, M. Igarashi, and M. Narita, “A glomerular permeability factor produced by human T cell hybridomas,” Kidney International, vol. 40, no. 3, pp. 453–460, 1991. View at Google Scholar · View at Scopus
  5. C. Ponticelli, “Recurrence of focal segmental glomerulosclerosis (FSGS) after renal transplantation,” Nephrology Dialysis Transplantation, vol. 25, pp. 25–31, 2010. View at Google Scholar
  6. A. Iharada, K. Kaneko, S. Tsuji, M. Hasui, S. Kanda, and T. Nishiyama, “Increased nitric oxide production by T- and B-cells in idiopathic nephrotic syndrome,” Pediatric Nephrology, vol. 24, no. 5, pp. 1033–1038, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  7. J. Dantal, Y. Godfrin, R. Koll et al., “Antihuman immunoglobulin affinity immunoadsorption strongly decreases proteinuria in patients with relapsing nephrotic syndrome,” Journal of the American Society of Nephrology, vol. 9, no. 9, pp. 1709–1715, 1998. View at Google Scholar · View at Scopus
  8. K. Benz, J. Dötsch, W. Rascher, and D. Stachel, “Change of the course of steroid-dependent nephrotic syndrome after rituximab therapy,” Pediatric Nephrology, vol. 19, no. 7, pp. 794–797, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  9. K. Nozu, K. Iijima, M. Fujisawa, A. Nakagawa, N. Yoshikawa, and M. Matsuo, “Rituximab treatment for posttransplant lymphoproliferative disorder (PTLD) induces complete remission of recurrent nephrotic syndrome,” Pediatric Nephrology, vol. 20, no. 11, pp. 1660–1663, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  10. M. D. Pescovitz, B. K. Book, and R. A. Sidner, “Resolution of recurrent focal segmental glomerulosclerosis proteinuria after rituximab treatment,” New England Journal of Medicine, vol. 354, no. 18, pp. 1961–1963, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  11. D. Hristea, K. Hadaya, N. Marangon et al., “Successful treatment of recurrent focal segmental glomerulosclerosis after kidney transplantation by plasmapheresis and rituximab,” Transplant International, vol. 20, no. 1, pp. 102–105, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  12. S. D. Marks and M. McGraw, “Does rituximab treat recurrent focal segmental glomerulosclerosis post-renal transplantation?” Pediatric Nephrology, vol. 22, no. 1, pp. 158–160, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  13. A. El-Firjani, S. Hoar, J. Karpinski, R. Bell, M. J. Deschenes, and G. A. Knoll, “Post-transplant focal segmental glomerulosclerosis refractory to plasmapheresis and rituximab therapy,” Nephrology Dialysis Transplantation, vol. 23, no. 1, p. 425, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  14. T. N. Meyer, F. Thaiss, and R. A. K. Stahl, “Immunoadsorbtion and rituximab therapy in a second living-related kidney transplant patient with recurrent focal segmental glomerulosclerosis,” Transplant International, vol. 20, no. 12, pp. 1066–1071, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  15. N. Kamar, S. Faguer, L. Esposito et al., “Treatment of focal segmental glomerular sclerosis with rituximab: 2 case reports,” Clinical Nephrology, vol. 67, no. 4, pp. 250–254, 2007. View at Google Scholar · View at Scopus
  16. J. Gossmann, E. H. Scheuermann, S. Porubsky, H. G. Kachel, H. Geiger, and I. A. Hauser, “Abrogation of nephrotic proteinuria by rituximab treatment in a renal transplant patient with relapsed focal segmental glomerulosclerosis,” Transplant International, vol. 20, no. 6, pp. 558–562, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  17. T. Apeland and A. Hartmann, “Rituximab therapy in early recurrent focal segmental sclerosis after renal transplantation,” Nephrology Dialysis Transplantation, vol. 23, no. 6, pp. 2091–2094, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  18. J. K. J. Deegens and J. F. M. Wetzels, “Rituximab for plasma exchange-dependent recurrent focal segmental glomerulosclerosis after renal transplantation,” NDT Plus, vol. 1, no. 2, pp. 85–88, 2008. View at Publisher · View at Google Scholar · View at Scopus
  19. J. M. Yabu, B. Ho, J. D. Scandling, and F. Vincenti, “Rituximab failed to improve nephrotic syndrome in renal transplant patients with recurrent focal segmental glomerulosclerosis,” American Journal of Transplantation, vol. 8, no. 1, pp. 222–227, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  20. U. S. Bayrakci, E. Baskin, H. Sakalli, H. Karakayali, and M. Haberal, “Rituximab for post-transplant recurrences of FSGS,” Pediatric Transplantation, vol. 13, no. 2, pp. 240–243, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  21. L. J. Hickson, M. Gera, H. Amer et al., “Kidney transplantation for primary focal segmental glomerulosclerosis: outcomes and response to therapy for recurrence,” Transplantation, vol. 87, no. 8, pp. 1232–1239, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  22. M. Rodríguez-Ferrero, J. Ampuero, and F. Anaya, “Rituximab and chronic plasmapheresis therapy of nephrotic syndrome in renal transplantation patients with recurrent focal segmental glomerulosclerosis,” Transplantation Proceedings, vol. 41, no. 6, pp. 2406–2408, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  23. L. D. Strologo, I. Guzzo, C. Laurenzi et al., “Use of rituximab in focal glomerulosclerosis relapses after renal transplantation,” Transplantation, vol. 88, no. 3, pp. 417–420, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  24. V. Freiberger, K. Amann, U. Heemann, and H. Frank, “Effect of a triple blockade of the renin-angiotensin-system in recurrent focal segmental glomerulosclerosis after kidney transplantation,” Transplant International, vol. 22, no. 11, pp. 1110–1113, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  25. R. Grenda, W. Jarmużek, B. Piatosa, and J. Rubik, “Long-term effect of rituximab in maintaining remission of recurrent and plasmapheresis-dependent nephrotic syndrome post-renal transplantation—case report,” Pediatric Transplantation, vol. 15, no. 6, pp. E121–E125, 2011. View at Publisher · View at Google Scholar · View at PubMed
  26. C. Sethna, C. Benchimol, H. Hotchkiss et al., “Treatment of recurrent focal segmental glomerulosclerosis in pediatric kidney transplant recipients: effect of rituximab,” Journal of Transplantation, vol. 2011, Article ID 389542, 2011. View at Google Scholar
  27. A. Prytula, K. Iijima, K. Kamei et al., “Rituximab in refractory nephrotic syndrome,” Pediatric Nephrology, vol. 25, no. 3, pp. 461–468, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  28. M. Vinai, P. Waber, and M. G. Seikaly, “Recurrence of focal segmental glomerulosclerosis in renal allograft: an in-depth review,” Pediatric Transplantation, vol. 14, no. 3, pp. 314–325, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  29. C. Wei, S. El Hindi, J. Li et al., “Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis,” Nature Medicine, vol. 17, no. 8, pp. 952–960, 2011. View at Publisher · View at Google Scholar · View at PubMed
  30. D. Haffner and D. C. Fischer, “Nephrotic syndrome and rituximab: facts and perspectives,” Pediatric Nephrology, vol. 24, no. 8, pp. 1433–1438, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  31. V. Guigonis, A. Dallocchio, V. Baudouin et al., “Rituximab treatment for severe steroid- or cyclosporine-dependent nephrotic syndrome: a multicentric series of 22 cases,” Pediatric Nephrology, vol. 23, no. 8, pp. 1269–1279, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  32. P. Ravani, A. Magnasco, A. Edefonti et al., “Short-term effects of rituximab in children with steroid- and calcineurin-dependent nephrotic syndrome: a randomized controlled trial,” Clinical Journal of the American Society of Nephrology, vol. 6, no. 6, pp. 1308–1315, 2011. View at Publisher · View at Google Scholar · View at PubMed
  33. L. E. Hultin, M. A. Hausner, P. M. Hultin, and J. V. Giorgi, “CD20 (Pan-B cell) antigen is expressed at a low level on a subpopulation of human T lymphocytes,” Cytometry, vol. 14, no. 2, pp. 196–204, 1993. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  34. A. R. Jazirehi, S. Huerta-Yepez, G. Cheng, and B. Bonavida, “Rituximab (chimeric anti-CD20 monoclonal antibody) inhibits the constitutive nuclear factor-κB signaling pathway in non-Hodgkin's lymphoma B-cell lines: role in sensitization to chemotherapeutic drug-induced apoptosis,” Cancer Research, vol. 65, no. 1, pp. 264–276, 2005. View at Google Scholar · View at Scopus
  35. A. Fornoni, J. Sageshima, C. Wei et al., “Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis,” Science Translational Medicine, vol. 3, no. 85, Article ID 85ra46, 2011. View at Publisher · View at Google Scholar · View at PubMed